“We can’t wait to be represented in Arizona and participate in what promises to be a big event for expanding the BergaMet brand,” said Decker
Boca Raton, FL (PRWEB) June 02, 2017
BergaMet NA, a company that develops a citrus bergamot supplement geared toward helping people find relief from metabolic syndrome symptoms, announced it will be in attendance at this June’s Weight Management, Sports Nutrition and Vitamin Efficient Program Planning Session (EPPS) in Chandler, Arizona.
The EPPS, an ECRM event, will give representatives from BergaMet NA a chance to sit down with major retail buyers in the American market, and demonstrate and discuss their product. The event takes place from June 25 to June 30.
“This is an exciting opportunity for us at BergaMet,” said Logan Decker, Director of Operations for BergaMet NA. “Not often do you have the chance to have face-to-face meetings with so many influential retail buyers at once. We strongly believe in the quality and effectiveness of our supplement, and believe the buyers at the conference will be impressed as well. We’re looking forward to getting to Arizona and forming relationships with these companies that will help us to continue increasing our market share across the United States.”
BergaMet NA began distributing the BergaMet supplements in 2016 after its founders became aware of the numerous benefits of the bergamot citrus fruit, especially those grown in the Calabrian region of Italy. The bergamot fruit grown in that region has a higher polyphenol count than fruits grown anywhere in the world, which means it has even more benefits for the cardiovascular system. Therefore, BergaMet NA exclusively uses those Italian fruits in its supplements, and brings those benefits to the people of North America.
Previous investigations have shown BergaMet™ monotherapy to be a powerful cardiometabolic regulator that routinely improves vascular health, lowers cholesterol, addresses all components of the metabolic syndrome and significantly normalizes liver function in patients with fatty liver disorders.
In a study completed in 2014, 77 patients with elevated LDL and triglycerides were divided into four groups to investigate the lipid lowering and vascular protective effects of placebo, BergaMet alone, rosuvastatin alone and their combination. The combination of BergaMet 1000 mg with rosuvastatin 10 mg or 20mg demonstrated an enhanced effect on all lipid parameters and significant increments in biomarkers of vascular protection and reductions in oxidative stress. As stated by Professor Vincenzo Mollace, “the paper shows, for the first time, that BergaMet leads physicians to a better management of statin-based treatment of hyperlipemia. Moreover the added value for using BergaMet in combination with statins is represented by significant improvement of serum triglyceride and glycemia leading to better vasoprotection.
BergaMet comes in several forms, each of which is designed to have its own specific benefits. The Mega+O supplement is a standard and a big seller for the company, as it is geared toward people with high counts of “bad” LDL cholesterol and triglycerides and low counts of “good” HDL cholesterol. BergaMet Pro+ provides many of the same benefits, but is 35 percent more potent, which makes it a great option for people who need additional help managing their cholesterol levels.
“We can’t wait to be represented in Arizona and participate in what promises to be a big event for expanding the BergaMet brand,” said Decker.
For more information about BergaMet NA and its products, visit http://www.bergametna.com.